Boehringer Ingelheim GmbH presented Phase Ib results and Bayer AG reported Phase I/II data for their HER2 inhibitors at World Conference on Lung Cancer (WCLC) that showed greater response rates for their oral drugs in previously treated non-small cell lung cancer (NSCLC) with HER2 mutations than seen with the only approved therapy in this indication, the AstraZeneca PLC/Daiichi Sankyo Co., Ltd. HER2-directed ADC Enhertu (trastuzumab deruxtecan).
Key Takeaways
-
HER2 tyrosine kinase inhibitors from Boehringer Ingelheim and Bayer showed promising efficacy in Phase Ib and Phase I/II clinical trials with better response rates than seen with the HER2 ADC Enhertu in NSCLC.
-
Both drugs have higher rates of diarrhea than AstraZeneca/Daiichi’s Enhertu, which could be challenging in the treatment of patients that currently have few options
However, the efficacy gains for Boehringer’s zongertinib and Bayer’s BAY 2927088 presented in a 9 September plenary session at the WCLC meeting came with a safety and tolerability trade-off of much higher levels of diarrhea
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
